Kodiak Sciences Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Segment Information
- Segment Information
The Company operates and manages its business asone operatingand reportable segment, which is the business of researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. The chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM uses net loss to allocate resources and assess performance when making decisions on the timing and extent of the Company's development programs for its product candidates. The assets are managed on a consolidated basis as reported on the consolidated balance sheets.
The significant expense categories within net loss are presented on the consolidated statements of operations. The research and development expenses have been disaggregated as follows (in thousands):
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Tarcocimab program expenses | $54,049 | $39,496 | $90,513 |
| KSI-501 and KSI-101 program expenses | 28,980 | 8,495 | 7,264 |
| ABC Platform and other program expenses | 23,776 | 12,915 | 20,997 |
| Payroll and personnel expenses | 56,082 | 45,522 | 65,382 |
| Facilities and other research and development expenses | 19,486 | 19,667 | 22,142 |
| Total research and development expenses | $182,373 | $126,095 | $206,298 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.